An economic evaluation of home management of malaria in Uganda: an interactive Markov model.
BACKGROUND
Home management of malaria (HMM), promoting presumptive treatment of febrile children in the community, is advocated to improve prompt appropriate treatment of malaria in Africa. The cost-effectiveness of HMM is likely to vary widely in different settings and with the antimalarial drugs used. However, no data on the cost-effectiveness of HMM programmes are available.


RESULTS
A Markov model was constructed to estimate the cost-effectiveness of HMM as compared to conventional care for febrile illnesses in children without HMM. The model was populated with data from Uganda, but is designed to be interactive, allowing the user to adjust certain parameters, including the antimalarials distributed. The model calculates the cost per disability adjusted life year averted and presents the incremental cost-effectiveness ratio compared to a threshold value. Model output is stratified by level of malaria transmission and the probability that a child would receive appropriate care from a health facility, to indicate the circumstances in which HMM is likely to be cost-effective. The model output suggests that the cost-effectiveness of HMM varies with malaria transmission, the probability of appropriate care, and the drug distributed. Where transmission is high and the probability of appropriate care is limited, HMM is likely to be cost-effective from a provider perspective. Even with the most effective antimalarials, HMM remains an attractive intervention only in areas of high malaria transmission and in medium transmission areas with a lower probability of appropriate care. HMM is generally not cost-effective in low transmission areas, regardless of which antimalarial is distributed. Considering the analysis from the societal perspective decreases the attractiveness of HMM.


CONCLUSIONS
Syndromic HMM for children with fever may be a useful strategy for higher transmission settings with limited health care and diagnosis, but is not appropriate for all settings. HMM may need to be tailored to specific settings, accounting for local malaria transmission intensity and availability of health services.
Lubell
Yoel
Y
Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand. yoel@tropmedres.ac
Mills
Anne J
AJ
Whitty
Christopher J M
CJ
Staedke
Sarah G
SG
D000962:Antimalarials / Q000191:economics / Q000600:supply & distribution / Q000627:therapeutic use; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D004338:Drug Combinations; D006699:Home Care Services / Q000191:economics*; D006801:Humans; D008288:Malaria / Q000188:drug therapy / Q000191:economics / Q000451:nursing*; D008390:Markov Chains; D008962:Models, Theoretical; D014454:Uganda; D000078329:Workforce
D000962:Antimalarials; D004338:Drug Combinations
Nature. 2006 Nov 23;444 Suppl 1:39-48
17159893
Acta Trop. 2005 Sep;95(3):305-15
16098946
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):128-32
18165484
PLoS Med. 2005 Jul;2(7):e190
16033307
Trends Parasitol. 2003 Aug;19(8):363-9
12901938
PLoS Med. 2007 Nov 6;4(11):e309
17988171
Parassitologia. 1999 Sep;41(1-3):241-6
10697862
JAMA. 2007 May 23;297(20):2210-9
17519410
PLoS One. 2011 Feb 24;6(2):e17439
21390277
Trop Med Int Health. 2004 Jan;9(1):125-32
14728616
Malar J. 2006 Dec 15;5:124
17173675
Trop Med Int Health. 2008 Jun;13(6):771-83
18363586
Trop Med Int Health. 2002 Dec;7(12):1042-6
12460395
Lancet. 2004 Nov 27-Dec 3;364(9449):1950-7
15567011
PLoS Med. 2005 Nov;2(11):e330
16187798
Malar J. 2006 Jul 22;5:60
16859565
Lancet Infect Dis. 2003 Feb;3(2):99-102
12560195
PLoS Clin Trials. 2007 May 18;2(5):e20
17525792
Trans R Soc Trop Med Hyg. 2003 May-Jun;97(3):325-30
15228253
Am J Trop Med Hyg. 2001 Jan-Feb;64(1-2 Suppl):iv-vii
11425185
Lancet. 2002 Dec 21-28;360(9350):2031-8
12504399
Lancet. 2009 May 9;373(9675):1623-31
19362361
Trop Med Int Health. 2005 Jan;10(1):1-2
15655007
Malar J. 2009 Sep 15;8:213
19754955
Malar J. 2007 Oct 08;6:134
17922916
Trop Med Int Health. 2005 Jun;10(6):621-2
15941428
PLoS Med. 2008 Feb;5(2):e38
18303939
Lancet. 2006 Feb 11;367(9509):482-8
16473125
Nat Med. 1999 Mar;5(3):340-3
10086393
Malar J. 2009 Dec 22;8:305
20028536
Malar J. 2007 Nov 15;6:151
18005422
Health Policy Plan. 2005 Jul;20(4):199-212
15965032
BMJ. 2010 Mar 05;340:c930
20207689
Trop Med Int Health. 2006 Jul;11(7):1003-16
16827701
Trop Med Int Health. 2004 Apr;9(4):445-50
15078262
Am J Public Health. 2001 Oct;91(10):1617-24
11574324
Malar J. 2006 May 15;5:40
16700903
PLoS One. 2009 Dec 14;4(12):e8184
20011529
Malar J. 2006 Apr 24;5:33
16635265
BMC Int Health Hum Rights. 2006 Mar 16;6:2
16539744
Trans R Soc Trop Med Hyg. 2007 Dec;101(12):1199-207
17945320
Trans R Soc Trop Med Hyg. 2003 Nov-Dec;97(6):647-54
16117956
Malar J. 2008 Jan 08;7:6
18182114
BMJ. 2008 Jan 26;336(7637):202-5
18199700
Acta Trop. 2004 Apr;90(2):211-4
15177148
PLoS Clin Trials. 2006 May;1(1):e7
16871329
PLoS Med. 2006 Oct;3(10):e373
17032059
Trop Med Int Health. 2001 Dec;6(12):986-91
11737835
Malar J. 2007 Jan 26;6:11
17257396
Malar J. 2008 Jun 11;7:106
18547415
Pharmacoeconomics. 1998 Apr;13(4):397-409
10178664
Am J Epidemiol. 1987 Aug;126(2):193-201
3605048